Singapore-based Austrianova presented additional safety and efficacy data from a second phase II pancreatic cancer clinical trial at the International Society for Cell and Gene Therapy (ISCGT) meeting held in Singapore on October 5 and 6. The trial data presented by Dr John Dangerfield, COO, Austrianova, reported phase II safety and efficacy data that confirmed and extended the data obtained from a previous phase I/II trial. <Click here to access full article>
